Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allo-APZ2-ACLF
- Development stage
- Unknown
- Lead developer
- RHEACELL
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
allo-APZ2-ACLF is an investigational allogeneic cell therapy developed by RHEACELL GmbH & Co. KG for the treatment of acute-on-chronic liver failure (ACLF). The product consists of highly purified, skin-derived mesenchymal stem cells (MSCs) that express the ATP-binding cassette member 5 (ABCB5) marker. These ABCB5-positive MSCs are isolated from the dermal tissue of healthy donors and expanded under GMP conditions. The therapeutic mechanism involves the intravenous administration of these cells, which are intended to modulate systemic and local immune responses and potentially promote liver regeneration in patients with severe liver failure. The therapy is currently being evaluated in Phase I/IIa clinical trials to assess its safety and efficacy (measured by changes in the MELD score) in patients with grade 2 and 3 acute-on-chronic liver failure.
- Other names
- allogeneic ABCB5-positive mesenchymal stem cellsskin-derived ABCB5+ MSCsallogeneic skin-derived ABCB5-positive mesenchymal stem cells
Beyond the preview
Go deeper on allo-APZ2-ACLF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allo-APZ2-ACLF.